BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Feeding and Anxiety Research

Executive Summary: BIIE 0246 is a highly selective neuropeptide Y Y2 receptor (Y2R) antagonist with nanomolar affinity (IC₅₀ = 3.3 nM) and robust in vivo and ex vivo validation in rat models (APExBIO). Its blockade of Y2R presynaptic inhibition enables precise modulation of NPY-mediated pathways, affecting feeding behavior, synaptic transmission, and anxiolytic phenotypes (Fan et al., 2024). BIIE 0246 is a white solid with MW 896.06 (C₄₉H₅₇N₁₁O₆), soluble up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol, and should be stored at 4°C (APExBIO). It is not approved for diagnostic or clinical use but is widely recommended for research into the neuropeptide Y signaling pathway and post-prandial satiety mechanisms (G-Protein-Coupled-Receptor.com). This article extends prior guidance by integrating recent findings on the adipose-neural axis and best-practice parameters for BIIE 0246 application.

Biological Rationale

The neuropeptide Y (NPY) system is fundamental to the regulation of feeding, anxiety, and synaptic inhibition in the central and peripheral nervous systems (Fan et al., 2024). The Y2 receptor (Y2R), a G-protein-coupled receptor (GPCR), is predominantly presynaptic and mediates negative feedback on NPY release. Y2R is implicated in energy homeostasis, satiety, and the modulation of stress responses. Evidence from stem cell-based coculture models demonstrates that the adipose-neural axis, via leptin and NPY signaling, directly modulates cardiac and metabolic phenotypes; Y2R antagonism is a critical tool for dissecting this pathway (Fan et al., 2024). BIIE 0246, as a selective antagonist, enables targeted inhibition of Y2R without significant cross-reactivity for other NPY receptor subtypes (HexetidineSource.com). This specificity is particularly relevant for feeding regulation research, anxiety disorder models, and studies on synaptic transmission.

Mechanism of Action of BIIE 0246

BIIE 0246 acts as a competitive antagonist at the neuropeptide Y Y2 receptor. It binds to Y2R with high affinity (IC₅₀ = 3.3 nM; K_i = 8–15 nM for PYY_3-36 binding), effectively blocking the receptor’s presynaptic inhibitory function (APExBIO). In rat hippocampal slices, BIIE 0246 suppresses NPY-induced inhibition of excitatory postsynaptic potentials, confirming its presynaptic locus of action. In peripheral tissue assays, such as rat colon contraction studies, BIIE 0246 fully blocks PYY_3-36-induced responses. In vivo, administration of BIIE 0246 reverses PYY(3-36)-induced hypophagia and increases feeding behavior in satiated rats, strongly supporting a role for Y2R in post-prandial satiety signaling (Fan et al., 2024). The compound also exhibits anxiolytic-like effects in the elevated plus-maze, consistent with central Y2R blockade (G-Protein-Coupled-Receptor.com).

Evidence & Benchmarks

• BIIE 0246 blocks Y2R with IC₅₀ = 3.3 nM and K_i = 8–15 nM in PYY_3-36 binding assays (APExBIO).
• In rat hippocampal slices, BIIE 0246 suppresses NPY-mediated presynaptic inhibition of excitatory postsynaptic potentials (Fan et al., 2024, DOI:10.1016/j.xcrm.2024.101559).
• BIIE 0246 completely blocks PYY_3-36-induced contraction in rat colon tissue ex vivo (APExBIO).
• In vivo, BIIE 0246 attenuates PYY(3-36)-induced reduction in feeding and increases food intake in satiated rats, demonstrating a role in post-prandial satiety (G-Protein-Coupled-Receptor.com).
• Behavioral assays show anxiolytic-like effects of BIIE 0246 in the elevated plus-maze (GENS-Bio.com).
• Recent studies implicate the NPY signaling axis in adipose-neural modulation of cardiac arrhythmias, highlighting the translational relevance of Y2R antagonism (Fan et al., 2024, DOI:10.1016/j.xcrm.2024.101559).

This article expands on prior overviews such as HexetidineSource.com, by directly relating BIIE 0246 benchmarks to recent mechanistic studies on the adipose-neural axis and arrhythmogenesis, providing a translational context for feeding and cardiovascular research.

Applications, Limits & Misconceptions

BIIE 0246 is validated for the following research applications:

• Dissection of NPY Y2 receptor function in synaptic inhibition and neurotransmission.
• Feeding behavior modulation and post-prandial satiety research in rodent models.
• Anxiolytic drug development and behavioral pharmacology using the elevated plus-maze.
• NPY receptor pharmacology in metabolic and cardiovascular disease models (Fan et al., 2024).
• Cell-based and tissue-based assays requiring high-affinity Y2R antagonism (Peptide-YY.com).

For guidance on Y2R antagonist assay workflows, see Peptide-YY.com. Unlike that Q&A-driven guide, this article integrates emerging literature on the adipose-neural axis and cross-system applications.

Common Pitfalls or Misconceptions

• Not a pan-NPY receptor antagonist: BIIE 0246 is selective for Y2R and does not block Y1, Y4, or Y5 receptors at nanomolar concentrations.
• Not suitable for diagnostic or therapeutic use: BIIE 0246 is for research use only, per APExBIO documentation (APExBIO).
• Limited chemical stability in solution: Solutions should not be stored long-term due to potential degradation; fresh preparation is recommended for each experiment.
• No direct clinical data: All efficacy and safety benchmarks are preclinical; translational relevance is supported by animal models only.
• Not effective in models lacking Y2R expression: Efficacy is dependent on Y2R presence; use validated cell lines or tissues.

Workflow Integration & Parameters

BIIE 0246 is provided as a white solid; the recommended solvent is DMSO (up to 67.2 mg/ml) or ethanol (up to 23.55 mg/ml). Store the powder at 4°C and avoid repeated freeze-thaw cycles. For in vitro assays, typical working concentrations range from 1 nM to 1 μM, depending on assay sensitivity and receptor expression levels. For in vivo rodent studies, consult published protocols for dosing regimens (e.g., 0.3–10 mg/kg i.p. or s.c.), noting that pharmacokinetics and CNS penetration may vary by species and route (Immunoglobulin-Single-Chain-Variable-Fragment-Acetyl.com). Shipments from APExBIO are supplied with blue ice to maintain stability. For detailed scenario-driven troubleshooting and assay optimization, see this comparative protocol guide, which this article updates by interlinking mechanistic translational findings from 2024.

Conclusion & Outlook

BIIE 0246 is a validated, high-affinity, and selective Y2 receptor antagonist for neuroscience, metabolic, and cardiovascular research. Its unique pharmacological profile enables dissecting NPY-mediated pathways in synaptic inhibition, feeding, and anxiety models. Ongoing studies on the adipose-neural axis and arrhythmogenesis expand the translational relevance of BIIE 0246 beyond traditional feeding behavior studies (Fan et al., 2024). Researchers are advised to follow APExBIO’s storage and handling recommendations and integrate recent literature for robust experimental design. For ordering and specifications, consult the BIIE 0246 product page.